Serum carnitine levels during the doxorubicin therapy. Its role in cardiotoxicity

Journal of Experimental and Clinical Cancer Research

Volumn 21, Issue 2, 2002, Pages 165-170

  Yaris, Nilgun ^a   Ceviz, N ^a   Coskun, T ^a   Akyuz C ^a   Buyukpamukcu M ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Cardiotoxicity; Carnitine; Childhood cancer; Doxorubicin

Indexed keywords

CARNITINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; METHOTREXATE; VINCRISTINE; ANTINEOPLASTIC ANTIBIOTIC;

ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLE; DOSE RESPONSE; FEMALE; HEART DISEASE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; MALE; MITRAL VALVE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SYSTOLE; BLOOD; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HEART; HEART FUNCTION TEST; PRESCHOOL CHILD; PROSPECTIVE STUDY;

ADOLESCENT; ANTIBIOTICS, ANTHRACYCLINE; CARNITINE; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DOXORUBICIN; FEMALE; HEART; HEART DISEASES; HEART FUNCTION TESTS; HUMAN; LYMPHOMA, NON-HODGKIN; MALE; PROSPECTIVE STUDIES; ANTIBIOTICS, ANTINEOPLASTIC; HUMANS;

EID: 0035991494     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. A clinico-pathologic analysis of adriamycine cardiotoxicity
2. Risk factors for doxorubicin induce congestive heart failure
3. Clinical spectrum of anthracyline antibiotic cardiotoxicity
4. Acute arythmogenicity of doxorubicin administration
5. Doxorubicin cardiotoxicity in children
6. Cardiac toxicity 4 to 20 years after completing anthracycline therapy
7. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood
8. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The Pediatric Oncology Group experiences
9. Cardioprotection by IRCF-187 against high dose anthracyline toxicity in children with malignant disease
10. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin
11. Dexrazoxane for protection against cardiotoxic effects of anthracyline in children
12. Clinical and non-invasive assessment of anthracycline cardiotoxicity: Perspectives on myocardial protection
13. Carnitine protection against adriamycin-induced cardiomyopathy in rats
14. L-carnitine
15. Carnitine: Metabolism and clinical chemistry
16. The therapeutic potential of carnitine in cardiovascular disorders
17. Carnitine defficiency presenting as familial cardiomyopathy: A treatable defects in carnitine transport
18. Plasma carnitine deficiency. Clinical observation in 51 pediatric patients
19. Reduction of cardiac toxicity of anthracyclines by L-carnitine: Preliminary overview of clinical data
20. Echocardiographic assessment of anthracycline cardiotoxicity during different therapeutic regimen
21. Methods for carnitin assay
22. Echo measurements in normal subjects from infancy to old age
23. Doppler echocardiographic evaluation of diastolic dysfunction
24. Dose-effect and structure-function relationships in doxorubicin cardiomyopathy
25. Early identification of anthracycline cardiomyopathy: Possibilities and implications
26. Early detection of doxorubicin cardiotoxicity: Interest of doppler echocardiographyic analysis of left ventricular filling dynamics
27. Pulsed doppler echocardiographic study of left ventricular filling in dilated cardiomyopathy
28. Left ventricular diastolic filling patterns associated with progressive anthracycline-induced myocardial damage: A prospective study
29. Increased urinary excretion of carnitine in patients treated with cisplatin
30. Thiodiglycolc acid is excreted by humans receiving ifosfamide and inhibits mitochondrial function in rats
31. The effect of valproic acid on plasma carnitine levels
32. Reversal of doxorubicin-induced cardiac metabolic damage by L-carnitine
33. Cytotoxic aldehydes as possible markers for childhood cancer
34. Defective myocardial carnitine metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart diseases
35. Doxorubicin (adriamycin): A critical review of free radical-dependent mechanism of cytotoxicty
36. Binding of adrymicine-Fe+ 3 complex to membrane phospholipids
37. Anthracycline glycoside-membrane interactions
38. Anthracycline cardiomyopathy monitored by morphological changes